Overview

A Bioequivalence Study of Daclatasvir Tablets and Bioavailability Studies of Daclatasvir and Asunaprevir

Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
Grps 1, 2, 3 "This study will be testing the performance of ASV and DCV pediatric chewable tablets. Grp #4 The purpose of this group is to support the marketing authorization of a DCV 90-mg tablet
Phase:
Phase 1
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Asunaprevir